00:00Increasing the possibility of transplantation today is a real opportunity.
00:04On the one hand, a better organization of the system is needed in the insertion of patients into the list,
00:10but it is certain that we have to face some complexities, some difficulties that arise from a quota
00:16approximately 10% of our patients on the waiting list are unable to have a transplant
00:24due to hypersensitivity, due to hyperimmunization that prevents transplantation.
00:30Now, on this topic, some steps forward have been made, some substantial ones which are also producing great results.
00:38such as the use of imlifidase which determines a temporary possibility of performing a cross-match negative transplant
00:47and therefore to subsequently monitor the progress of the transplant, or even innovative therapies that change the strategy itself,
00:54they change the general concept of approach to this topic.
00:58These strategies are based on the use of CAR-T or bispecific antibodies that are able to attack
01:06those plasma cells that produce antibodies and somehow get to the root of the problem
01:12and reduce the PRA, that is the hypersensitivity, that is to hit those antibodies that in a high way
01:22they can determine the risk of rejection and therefore hinder the possibility of carrying out the transplant.
01:30I believe that these two opportunities can have space in the future and as has also been seen in this congress
01:39are beginning to have a place in the scientific literature supported by a significant series of data
01:46which may perhaps bring some news for our patients in the future.
